Viferon 3.000.000 IU 10 pcs.

1 suppository VIFERON® 3000000 IU contains the active substance:

interferon alpha-2b human recombinant 3,000,000 IU,

Excipients:

ascorbic acid 0.0081 g,

sodium ascorbate 0.0162 g,

alpha tocopherol acetate 0.055 g,

disodium edetate dihydrate 0.0001 g,

polysorbate-80 0.0001 g,

cocoa butter 0.1941 g,

confectionery fat or cocoa butter substitute up to 1 g.

Interferon alpha-2b human recombinant has antiviral, immunomodulating, antiproliferative properties, inhibits the replication of RNA and DNA viruses. The immunomodulating properties of interferon alpha-2b, such as increased macrophage phagocytic activity, increased specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity.

In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which makes it possible to increase the efficiency of the body's own immune response to pathogenic microorganisms.

When using the drug, the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E is normalized, the functioning of the endogenous system of interferon alpha-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and also regenerating properties.

It has been established that when using the VIFERON® preparation, there are no side effects arising from the parenteral administration of interferon alpha-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.

Cocoa butter contains phospholipids, which allow synthetic toxic emulsifiers not to be used in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.

- acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy;

- infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy;

- chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis with severe activity complicated by cirrhosis of the liver;

- infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults as part of complex therapy;

- primary or recurrent herpes infection of the skin and mucous membranes, localized form, mild and moderate course, including the urogenital form in adults.

Viferon is approved for use from the 14th week of pregnancy.

It has no restrictions on the use during lactation.

Hypersensitivity to the drug.

In rare cases, the development of allergic reactions (skin rashes, itching) is possible.

These phenomena are reversible and disappear 72 hours after stopping the drug.

The drug is used rectally. 1 suppository contains human recombinant interferon alpha-2b as the active substance in the indicated dosages (150,000 IU, 500,000 IU, 1,000,000 IU, 3,000,000 IU).

Acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy.

The recommended dose for adults, including pregnant women and children over 7 years of age, is VIFERON® 500000 IU, 1 suppository 2 times a day after 12 hours daily for 5 days. According to clinical indications, therapy can be continued.

For children under 7 years of age, including newborns and premature babies with gestational age over 34 weeks, the use of the drug is recommended

VIFERON® 150,000 IU, 1 suppository 2 times a day after 12 hours daily for 5 days. According to clinical indications, therapy can be continued. A break between courses is 5 days.

The use of VIFERON® 150,000 IU is recommended for premature newborns with gestational age less than 34 weeks

1 suppository 3 times a day after 8 hours daily for 5 days.

According to clinical indications, therapy can be continued. A break between courses is 5 days.

Infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of complex therapy.

The recommended dose for newborns, including premature babies with a gestational age of more than 34 weeks, VIFERON® 150,000 IU daily, 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.

The use of the drug VIFERON® 150,000 IU daily, 1 suppository 3 times a day after 8 hours is recommended for premature newborns with gestational age less than 34 weeks. The course of treatment is 5 days.

The recommended number of courses for various infectious and inflammatory diseases: sepsis - 2-3 courses, meningitis - 1-2 courses, herpetic infection - 2 courses, enterovirus infection - 1-2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis, candidiasis, including visceral - 2-3 courses. A break between courses is 5 days. According to clinical indications, therapy can be continued.

Chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis with severe activity complicated by cirrhosis of the liver.

The recommended dose for adults is VIFERON® 3,000,000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Children under the age of 6 months are recommended 300,000-500,000 IU per day; from 6 to 12 months of age - 500,000 IU per day.

For children aged 1 year to 7 years, 3,000,000 IU are recommended per 1 m2 of body surface area per day.

5,000,000 IU per 1 m2 of body surface area per day is recommended for children over 7 years old.

The drug is used 2 times a day after 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Calculation of the daily dose of the drug for each patient is made by multiplying the recommended dose for a given age by the body surface area calculated by the nomogram for calculating the body surface area by height and weight according to Garford, Terry and Rourke. The calculation of a single dose is carried out by dividing the calculated daily dose by 2 injections, the resulting value is rounded up to the dosage of the suppository.

In cases of chronic viral hepatitis of pronounced activity and cirrhosis of the liver, prior to plasmapheresis and / or hemosorption, VIFERON® 150,000 IU is recommended for children under 7 years old; VIFERON® 500,000 IU over 7 years old, 1 suppository 2 times a day every 12 hours every day within 14 days.

Infectious and inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults, including pregnant women as part of complex therapy.

The recommended dose for adults is VIFERON® 500000 IU, 1 suppository 2 times a day after 12 hours daily for 5-10 days. According to clinical indications, therapy can be continued.

Pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation) are recommended to use the drug VIFERON® 500000 IU in 1 suppository

2 times a day after 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days (on the fourth day), 1 suppository 2 times a day after 12 hours. Then every 4 weeks until delivery VIFERON® 150,000 IU

1 suppository 2 times a day after 12 hours daily for 5 days.

If necessary, it is indicated before delivery (from 38 weeks of gestation) the use of the drug VIFERON® 500000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days.

Primary or recurrent herpes infection of the skin and mucous membranes, localized form, mild and moderate course, including the urogenital form in adults, including pregnant women.

The recommended dose for adults is VIFERON® 1,000,000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days or more with a recurring infection. According to clinical indications, therapy can be continued. It is recommended to start treatment immediately when the first signs of damage to the skin and mucous membranes appear (itching, burning, redness).

In the treatment of recurrent herpes, it is advisable to begin treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.

Pregnant women from the second trimester of pregnancy (starting from the 14th week of gestation) are recommended to use the drug VIFERON® 500000 IU in 1 suppository

2 times a day after 12 hours daily for 10 days, then for 9 days 3 times with an interval of 3 days (on the fourth day), 1 suppository 2 times a day after 12 hours. Then, every 4 weeks until the delivery of VIFERON® 150,000 IU, 1 suppository 2 times a day after 12 hours daily for 5 days. If necessary, it is indicated before delivery (from 38 weeks of gestation) the use of the drug VIFERON® 500000 IU, 1 suppository 2 times a day after 12 hours daily for 10 days.

For the treatment of a wide range of infectious and inflammatory diseases, Viferon can be used as part of combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.

There is evidence of the effectiveness of the use of the drug Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children older than 1 year; viral hepatitis in adults, acute respiratory viral infections, influenza, bronchial asthma, juvenile rheumatoid arthritis; meningeal form of tick-borne encephalitis; prostatitis of various etiologies; purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephritis.

Rectal suppositories